A detailed history of Us Bancorp \De\ transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 88 shares of JANX stock, worth $4,224. This represents 0.0% of its overall portfolio holdings.

Number of Shares
88
Previous 209 57.89%
Holding current value
$4,224
Previous $8,000 62.5%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$35.29 - $50.26 $4,270 - $6,081
-121 Reduced 57.89%
88 $3,000
Q2 2024

Aug 06, 2024

BUY
$35.12 - $64.78 $6,848 - $12,632
195 Added 1392.86%
209 $8,000
Q1 2024

May 07, 2024

SELL
$7.93 - $49.75 $602 - $3,781
-76 Reduced 84.44%
14 $0
Q1 2023

May 09, 2023

BUY
$11.25 - $22.21 $1,012 - $1,998
90 New
90 $1,000
Q3 2021

Nov 10, 2021

SELL
$20.7 - $34.69 $144 - $242
-7 Closed
0 $0
Q2 2021

Aug 05, 2021

BUY
$18.58 - $25.37 $130 - $177
7 New
7 $0

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.